3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other solid neoplasm
1
Conditions
Breast Neoplasms
4
Triple Negative Breast Neoplasms
3
Neuroectodermal Tumors, Primitive, Peripheral
2
Leukemia, Myeloid, Acute
2
Carcinoma, Renal Cell
2
Wilms Tumor
1
Squamous Cell Carcinoma of Head and Neck
1
Sarcoma, Ewing
1
Sarcoma
1
Rhabdomyosarcoma
1
Rhabdoid Tumor
1
Recurrence
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Osteosarcoma
1
Neuroblastoma
1
Neoplasms
1
Kidney Neoplasms
1
Hepatoblastoma
1
Endometrial Neoplasms
1
Colorectal Neoplasms
1
Central Nervous System Neoplasms
1
Carcinoma, Ovarian Epithelial
1
Carcinoma, Non-Small-Cell Lung
1
Advanced Solid Tumor
1
Advanced Ovarian Cancer
1
Interventions
Injections
13
toripalimab
12
pembrolizumab
4
atezolizumab
4
Gemcitabine
4
Carboplatin
4
Cisplatin
3
trastuzumab deruxtecan
2
tislelizumab
2
spartalizumab
2
lenvatinib
2
Pemetrexed
2
Paclitaxel
2
Oxaliplatin
2
Fluorouracil
2
Albumin-Bound Paclitaxel
2
talazoparib
1
sintilimab
1
penpulimab
1
olaparib
1
niraparib
1
nedaplatin
1
mirdametinib
1
enfortumab vedotin
1
conteltinib
1
Nivolumab
1
Magnetic Resonance Spectroscopy
1
Leucovorin
1
Letrozole
1
Irinotecan
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Advanced Solid Tumor
×
talazoparib
×
Clear all
NCT04497116
2025-10-21
TRESR
Repare Therapeutics
Phase 1/2
Completed
276 enrolled
33 charts